The Saul R. Korey Department of Neurology


NIH-funded research:

NINDS Stroke Trials Network - Regional Coordinating Stroke Center. Mark Mehler MD, Principal Investigator, in partnership with Mt. Sinai and NYU Langone Schools of Medicine: 

MISTIE III (Minimally Invasive Surgery Plus rt-PA forIntracerebral Hemorrhage Evacuation) is an international, Phase III, 500-patient clinical trial with the primary goal of defining a successful treatment for ICH. 

iDEF (Intracerebral hemorrhage deferoxamine trial): the study of deferoxamine mesylate in intracerebral hemorrhage

MaRISS (Mild and Rapidly Improving Stroke Study)

BASE (Ischemia Care Biomarker of Acute Stroke Etiology)

POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke)

Industry-funded research:

Biogen: natalizumab for acute stroke phase 2 clinical trial

Asubio: SUN13837 for acute ischemic stroke phase 2 clinical trial

Selection of recent and on-going intramural research:

Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack, NEJM 2016

A radiologist guide to the clinical scales used in the 2015 Endovascular Stroke Trials, Emerg Radiol 2016

Cardiac Magnetic Resonance Imaging: a New Tool to Identify Cardioaortic Sources in Ischemic Stroke, JNNP 2016

Stern Stroke Center Menu





Click here to log in